Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

Dr Marc Laniado made a choice to be more mindful of his own health - here's what he discovered, from 'exercise snacking' to ...

Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with ...

A global phase 3 trial enrolled mHSPC with ≥90% PTEN loss by IHC and randomized 1,012 patients to intermittent capivasertib plus abiraterone/prednisone versus ...

Hedy Phillips is a freelance lifestyle writer based in New York. While she's not writing on topics like living on a budget and tips for city dwelling, she can usually be found at a concert or ...

Using both PSMA PET and mpMRI before cognitive targeted biopsy improved specificity for clinically significant prostate cancer from 54.6% to 86.3%. For men undergoing evaluation for suspected prostate ...

Research is mixed on whether selenium supplements lower the risk of prostate cancer in older men. While studies have linked zinc deficiencies to prostate cancer, taking too much zinc can increase the ...

Ads for prostate supplements and home testing kits have been banned over concerns they could mislead vulnerable people or steer them away from appropriate medical advice. The Advertising Standards ...

A 47-year-old man who was accused of having more than 5,000 meth pills stashed inside a shoebox has pleaded guilty. Saugus man George Krabey pleaded guilty in Boston federal court to his role in a ...

Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop biochemical recurrence (BCR), which requires effective treatment to delay ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...